Dow Jones 10419.59 -2.46 9:08 am PST, September 25, 2005  NASDAQ 2116.84 +6.06 For info, visit access.smallcapnetwork.com S & P 500 1215.29 +0.67 Change your subscription status here Russell 2000 655.53 +4.37 VOLUME 05: ISSUE 73  Feature: Biophan - Rebound Imminent. Love or just like it, Biophan (OTCBB: BIPH), has been old reliable in the profit column for subscribers of the SmallCap Digest. In December of '03 when we first featured it at $.35, BIPH was completely unknown and possessed some interesting technology in the nanotechnology arena. Along came a deal with medical device behemoth Boston Scientific (NYSE: BSX), and it was off to the races. A ten bagger at the high of January in '05 from the early pricing, this the stock has been a microcap darling. Each and everytime BIPH  has succumbed to external market conditions, scooping up shares at the low end of the trading range has proven profitable for traders. Since Friday's close there have been two events that should send BIPH back up the charts to the $3 threshold. First, after the market closed on Friday, BIPH announced the filing of another 12 patents in the medical device technology arena, bringing the total to 200 patents.  Through the use of nanotechnology which doesn't require metal, manufacturers can now make implantable devices such as pacemakers "MRI Safe". With no metal parts, the devices will not heat up during image taking procedures. Enhancing the upside opportunity is the highly likely market rebound from the Hurricane Rita discount. Last week, the market had priced in a worst case scenario in the energy sector. Non energy related stocks were under significant pressure as investors headed to the sidelines to await reports of damage to America's energy infrastructure. Unlike Katrina, Rita petered out a bit before making landfall, and was downgraded to Hurricane Category 3 status before making landfall and passed a little to the east of refineries.  Since the market had priced in a worst case scenario, we believe many oversold stocks will rise with the tide of a rebounding market. BIPH has been old reliable for over a year when it blips down to the long term trend line. Each and every pullback has been met with a substantive rebound, and investors with the courage to step up when the stock was trading poorly have been greeted with impressive rallies and a stock which goes on to make a new high. If this stock has treated you well in the past, now is the time to return to the well for another profitable drink. We strongly recommend picking up shares of BIPH as the Hurricane Rita discount should prove an opportunity. Below is Friday's post close news release for your review:   Biophan Files Twelve New Patents in MRI Safety Expanding Intellectual Property Portfolio to More Than 200 Including International Filings Friday September 23, 4:01 pm ET   Innovations Enable Manufacturers of Pacemakers, Neurostimulators, and Other Medical Devices to Make Products MRI Safe ROCHESTER, N.Y--(BUSINESS WIRE)--Sept. 23, 2005-- Biophan Technologies, Inc. (OTCBB: BIPH - News; Frankfurt/FSE: BTN) a developer of next-generation biomedical technology, has announced the filing of twelve new patents, expanding the Company's extensive intellectual property portfolio to more than 200 patents, applications, or licenses. That total includes 156 pending and issued U.S. patents and another 46 international applications.    The twelve new patents teach how a tiny circuit can be added to minimize dangerous heating which can occur when devices such as pacemaker and neurostimulators leads are exposed to MRI signals. The circuits are powered by the energy in the MRI field and dissipate the energy so that heating does not occur. The circuits can be tuned to specific frequencies, such as the frequencies associated with 1.5 and 3.0 Tesla MRI machines. These circuits have been tested under worst-case conditions on representative devices, and can reduce heating to acceptable levels.  The twelve patents teach a variety of ways that these circuits can reduce heating on many types of medical devices that suffer from MRI safety limitations. These include many implantable devices, such as pacemakers, defibrillators, and neurostimulators, devices used for Parkinson's, epilepsy and pain control, as well as stimulation devices for obesity control, gastrointestinal and bladder control. In addition to implantable devices, this technology applies to devices used in interventional medicine, including catheters, guidewires, and other surgical tools.  "We anticipate a shift over the next several years, where virtually all biomedical devices currently contraindicated for MRI or experiencing imaging limitations, will be made both safe and compatible for use with MRI. Over $12 billion worth of devices are sold every year with these shortcomings," stated Michael Weiner, Biophan CEO. "It is unfortunate when a patient who needs to be staged for a cancer operation is denied access to an MRI machine because they have a pacemaker or other contraindicated implant. An even more tragic situation occurs when a patient is placed in an MRI machine in spite of the contraindication by a physician who is not aware of the implant, or who does not realize that MRI is dangerous when used with these devices. The FDA issued a new warning recently advising radiologists not to place patients with neurostimulators in MRI machines, as one patient went into a coma after the contraindication was not heeded.  "The optimal solution is for manufacturers to make their devices safe for use with MRI. Biophan has the technology to enable this, and there is now significant activity underway to help make future neurostimulators safe for use with MRI, and some increased activity on the part of pacemaker manufacturers," Mr. Weiner said. "There is no ethical justification to continue to ship medical devices that are not safe for use with MRI, and we are pleased to note the increasing activity on the part of many of the major manufacturers to move in this direction."  As previously announced, Biophan has provided a license for MRI safety and image compatibility, covering multiple products to leading medical device manufacturer Boston Scientific (NYSE: BSX - News). Discussions are underway with many other medical device manufacturers in these areas as well.  To learn more about MRI safety and medical devices, visit Biophan's web site at http://www.biophan.com/mrisafety.php or www.biophan.com.  About Biophan Technologies  Biophan develops and markets cutting-edge technologies designed to make biomedical devices safe and image compatible with the magnetic resonance imaging (MRI) environment. The Company develops technologies that enable implanted medical systems such as pacemakers, interventional surgical devices such as catheters and guidewires, and devices such as stents to be safely and effectively imaged under MRI. Biophan is developing these same technologies to provide new MRI contrast agents. Other applications include drug delivery and power systems derived from body heat. Four Biophan technologies include advances in nanotechnology and thin film coatings. Committed to growth through innovation and developmental leadership, Biophan and its licensors now hold a total of 156 U.S. patents, licenses, or applications. This total includes 41 issued U.S. patents, 9 recently-allowed applications that will issue as patents in the near future, and 106 pending applications at various stages of examination at the U.S. Patent and Trademark Office, plus international applications. The patents cover areas including nanotechnology (nanomagnetic particle coatings), medical device designs, radio frequency filters, polymer composites, thermoelectric materials for batteries generating power from body heat, and photonics. Biophan has joint development and licensing agreements with Boston Scientific and NASA's Ames Center for Nanotechnology. Biophan's goal is to make all biomedical devices capable of safely and successfully working with MRI, and delivering other technologies which will improve quality of life. For more information, please visit www.biophan.com.  Cautionary Statement Regarding Forward-Looking Statements  Certain statements included in this press release may constitute forward-looking statements within the meaning of applicable securities laws. These statements reflect what Biophan anticipates, expects, or believes may happen in the future. Biophan's actual results could differ materially from the outcome or circumstance expressed or implied by such forward-looking statements as a result of a variety of factors including, but not limited to: Biophan's ability to develop its technologies; the approval of Biophan's patent applications; the successful implementation of Biophan's research and development programs; the ability of Biophan to demonstrate the effectiveness of its technology; the acceptance by the market of Biophan's technology and products incorporating such technology, the ability of Biophan to effectively negotiate and enter into contracts with medical device manufacturers for the licensing of Biophan's technology; competition; the ability of Biophan to raise capital to fund its operating and research and development activities until it generates revenues sufficient to do so; and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in Biophan's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with Biophan's periodic filings with the SEC which are incorporated herein by reference. The forward-looking statements contained herein are made only as of the date of this press release, and Biophan undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.      Contact:  Biophan Technologies, Inc. Carolyn Hotchkiss, 585-214-2407 or Press Interviews: Jennifer Gould, 212-843-8037     Source: Biophan Technologies, Inc.     We Value Your Feedback Got comments, questions or suggestions? Send 'em on over: Editor@smallcapnetwork.com If you wish to send a written request or inquiry, please send it to our physical address: TGR Group, LLC 3525 Del Mar Heights Rd #334 San Diego, CA 92130 Subscribe Information is power and timely information is profitable. Become informed and profit from SmallCapDigest Profiles and Trading Alerts by becoming a Preferred Member today. There is no cost associated with your email subscription. Add your email address below and make sure to check your email inbox and confirm your opt-in request to start receiving the SmallCapDigest Email Newsletter on a regular basis. To ensure newsletter delivery, you can add any additional email addresses you may have to the SmallCapDigest Member List. Receiving the SmallCapDigest Newsletter in multiple locations is the best way of making sure you don't miss the next investing or trading opportunity! For web based email addresses, the SmallCapDigest recommends @yahoo.com or @aol.com for timely and reliable email newsletter delivery. Subscribe Here Note: Your email address will be kept strictly confidential, and will not be shared with any other entity for any purpose at any time. If you no longer wish to receive the SmallCapDigest, simply follow the instructions located at the bottom of every SmallCapDigest Newsletter Edition. Unsubscribe Here D I S C L A I M E R: The SmallCap Digest is an independent electronic publication committed to providing our readers with factual information on selected  publicly traded companies. SmallCap Digest is not a licensed investment professional or broker-dealer. All companies are chosen on the basis of certain financial analysis and other pertinent criteria with a view toward  maximizing the upside potential for investors while minimizing the downside risk, whenever possible.  Moreover, as detailed below, this publication accepts compensation from third party consultants and/or companies which it features for the publication and circulation of the SmallCap Digest or representation on SmallCapNetwork.net.  Likewise, this newsletter is owned by TGR Group, LLC.  To the degrees enumerated herein,  this newsletter should not be regarded as an independent publication. Visit Here to view our compensation on every company we have ever covered, or visit the following web address:  http://access.smallcapnetwork.com/compensation_disclosure.html for our full compensation disclosure and http://access.smallcapnetwork.com/short_term_alerts.html for Trading Alerts compensation and disclosure. TGR Group LLC has been paid fees of $65,000 in total directly by Biophan Technologies, Inc. for reporting on the Company. Additionally, TGR Group LLC was paid a fee of $25,000 by Trilogy Capital for reporting on the Company in August of 2004. Additionally, some of the companies featured in the SmallCap Digest Newsletter pay an ESP (Electronic Service Provider) fee of $3,000 per month to an affiliated Technology Company for electronic delivery of this newsletter and other web related technology services. All statements and expressions are the sole  opinions of the editors and are subject to change without notice. A profile, description, or other mention of a company in the newsletter is neither an offer nor solicitation to buy or sell any securities  mentioned. While we believe all sources of information to be factual and reliable, in no way do we represent or guarantee the accuracy thereof, nor the statements made herein. From time to time TGR Group LLC sells shares in the open market it receives as compensation for coverage of client companies. Since the shares are received as compensation for services as previously disclosed, and not for investment purposes, the editors do not view the sale of the shares as contradictory to any advice delivered in the content. This should be viewed as a conflict of interest by shareholders or prospective shareholders of the client companies. The editor, members of the editor's family, and/or entities with  which the editor is affiliated aside from TGR Group LLC itself, are forbidden by company policy to own, buy, sell or otherwise trade stock for their own benefit in the companies who appear in the publication unless specifically disclosed in the newsletter. The profiles, critiques, and other editorial content of the SmallCap Digest and SmallCapNetwork.net may contain statements that appear forward as it relates to the expected capabilities of the companies mentioned herein. THE READER SHOULD VERIFY ALL CLAIMS AND DO THEIR OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES MENTIONED. INVESTING IN  SECURITIES IS SPECULATIVE AND CARRIES A HIGH DEGREE OF RISK. THE INFORMATION FOUND IN THIS PROFILE IS PROTECTED BY THE COPYRIGHT LAWS OF THE UNITED STATES AND MAY NOT BE COPIED, OR REPRODUCED IN ANY WAY WITHOUT THE EXPRESSED, WRITTEN  CONSENT OF THE EDITORS OF SMALLCAPNETWORK.NET. We encourage our readers to invest carefully and read the investor information available at the web sites of  the Securities and Exchange Commission ("SEC") at http://www.sec.gov and/or the National Association of Securities Dealers ("NASD") at http://www.nasd.com. We also strongly recommend that you read the SEC advisory to investors concerning Internet Stock Fraud, which can be found at  http://www.sec.gov/consumer/cyberfr.htm . Readers can review all public filings by companies at the SEC's EDGAR page. The NASD has published information on how to invest carefully at its web site.